STK3 is a therapeutic target for a subset of acute myeloid leukemias

  • Acute myeloid leukemia (AML) is characterized by uncontrolled proliferation and accumulation of immature myeloblasts, which impair normal hematopoiesis. While this definition categorizes the disease into a distinctive group, the large number of different genetic and epigenetic alterations actually suggests that AML is not a single disease, but a plethora of malignancies. Still, most AML patients are not treated with targeted medication but rather by uniform approaches such as chemotherapy. The identification of novel treatment options likely requires the identification of cancer cell vulnerabilities that take into account the different genetic and epigenetic make-up of the individual tumors. Here we show that STK3 depletion by knock-down, knock-out or chemical inhibition results in apoptotic cells death in some but not all AML cell lines and primary cells tested. This effect is mediated by a premature activation of cyclin dependent kinase 1 (CDK1) in presence of elevated cyclin B1 levels. The anti-leukemic effects seen in both bulk and progenitor AML cells suggests that STK3 might be a promising target in a subset of AML patients.

Download full text files

Export metadata

Metadaten
Author:Aylin Camgoz, Maciej Paszkowski-Rogacz, Shankha Satpathy, Martin Wermke, Martin V. Hamann, Malte von Bonin, Chunaram Choudhary, Stefan Knapp, Frank Buchholz
URN:urn:nbn:de:hebis:30:3-466012
DOI:https://doi.org/10.18632/oncotarget.25238
ISSN:1949-2553
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/29876001
Parent Title (English):OncoTarget
Publisher:Impact Journals LLC
Place of publication:[s. l.]
Document Type:Article
Language:English
Year of Completion:2018
Date of first Publication:2018/05/22
Publishing Institution:Universit├Ątsbibliothek Johann Christian Senckenberg
Release Date:2018/06/14
Tag:AML; STK3; UCN-01; mitosis; personalized medicine
Volume:9
Issue:39
Page Number:16
First Page:25458
Last Page:25473
Note:
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
HeBIS-PPN:433827041
Institutes:Biochemie, Chemie und Pharmazie / Pharmazie
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universit├Ątspublikationen
Licence (German):License LogoCreative Commons - Namensnennung 3.0